Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.
about
Oligonucleotide-assisted cleavage and ligation: a novel directional DNA cloning technology to capture cDNAs. Application in the construction of a human immune antibody phage-display libraryMonoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin DrugsMolecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxinA Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic α-Exosite Binding RegionMolecular imaging of cancer cells using a bacteriophage-based 129Xe NMR biosensor.Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors.Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.Identification of recombinant antibodies against multiple distinct toll-like receptors by homolog mining a single immune scFv phage librarySelection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype BPredicting protein evolution in vitro by phage escape technology.Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library.Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies.Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating.Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes.Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralizationPotent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.Epitope mapping of botulinum neurotoxins light chains.Transferring the characteristics of naturally occurring and biased antibody repertoires to human antibody libraries by trapping CDRH3 sequencesPotent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain.Clostridium botulinum: a bug with beauty and weapon.Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxinDevelopment of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype BIsolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy.N-Terminal labeling of filamentous phage to create cancer marker imaging agents.Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.Tetanus Neurotoxin Neutralizing Antibodies Screened from a Human Immune scFv Antibody Phage Display LibraryQuantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodiesIdentification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies.Investigating novel therapeutic targets and molecular mechanisms to treat botulinum neurotoxin A intoxication.Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN)The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies.
P2860
Q24805914-261EDEDD-5A1A-4157-8DE7-D3158BCD40BAQ26863621-01344C86-45F9-4E67-B9BB-63F7F832005AQ27643327-63C04AD6-BF8C-480E-9338-E8D3EE61CF01Q27659624-6ED386A8-5D5E-4426-8617-4E3F7095F1A0Q30612000-A3684E59-0E55-463D-BE7E-FEC66F37064BQ30862040-DA3B7156-71D4-416A-BBDF-F0C86731F7CAQ33249268-E46709E4-E352-4D36-A833-14B8FD1AD4DFQ33261279-1FED5DA7-641A-41B5-A5D2-F2F4FA02EC20Q33385401-F1B74606-A7FF-4AA5-89D7-863FA4455EA9Q33396168-2E6BF018-6120-4A9A-8968-859FBB707CCFQ33401273-424E7A6F-FAD0-4AC6-ACA9-42AC05A03385Q33499630-0E3D69C4-4563-4FD1-B7A6-5E73C9A03596Q33523442-2CA0723C-0C7B-4888-9446-DCB83AC2B051Q33526251-B51B1DC0-3BAF-41AD-8817-F53C10282B4AQ33531378-609E9A37-523F-4A89-AA8C-08459D3596A8Q33680867-E0E8E515-85D7-4BAF-B0F6-7159E0AED8C7Q33739700-AA3E4F5C-9AA6-40FC-8B4C-D2A68F548D41Q33888291-B913AFE3-218A-4372-A9DE-BEA041B9E92FQ34034156-1DF9BF06-FA9A-47CA-9148-E5F79A9DF785Q34038244-70ED5BD7-9087-4E3E-B754-8C88B1FDF8D6Q34393419-FF105CC7-FF7E-4F84-A6CB-43758E3C2077Q34399160-850368DC-518D-4C1E-A6D8-6AC7C66A91ACQ34405710-6E9BA0FF-EA1A-46E9-8B76-A40EB118B543Q34412430-2CA6A506-57ED-4A2E-A65F-DA4BFA06EBACQ34571717-FA7D3A08-51C6-4FCF-BC04-4E47B2082177Q35779652-5CDD5E10-61FD-4E32-89C5-8B0A86C43DD2Q35780060-E1A41C77-20E8-47AB-A3C6-53EC4E0F5F8CQ35869311-E9102938-3670-4949-87A2-EFA1C2DB85B3Q36023082-8E989052-ED90-4726-AC23-7B748070BBB1Q36033286-FD559423-E4AF-44E2-A956-47421A4148C7Q36213754-BE0A275F-FEC9-468E-A5C9-E1C38A36CF91Q36319370-66372A88-4AD5-4327-8A64-BE02DCB5006CQ36816587-E90092C7-E7EC-4491-8B90-D6454AF4BAAFQ37285685-3EB050F5-20B2-4507-A94B-15FABA6A97CBQ37308221-91CE4C1E-69AD-4F62-B0A8-B9419985A071Q37323247-608FBDF3-1EF4-4394-BD0B-0BF03AE6E3B0Q38337915-16CB5A82-2C57-4078-948E-360141E97904Q40149882-BA9151F1-0A9C-4D54-B5A2-B5F3CAE6C6D6Q42095229-AC32ADE6-6A1D-4E5F-A0CE-D913C775E290Q45235847-8699031A-3541-4CE4-954E-E6DCBD8054C9
P2860
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Genetic and immunological comp ...... -immune human phage libraries.
@ast
Genetic and immunological comp ...... -immune human phage libraries.
@en
type
label
Genetic and immunological comp ...... -immune human phage libraries.
@ast
Genetic and immunological comp ...... -immune human phage libraries.
@en
prefLabel
Genetic and immunological comp ...... -immune human phage libraries.
@ast
Genetic and immunological comp ...... -immune human phage libraries.
@en
P2093
P1433
P1476
Genetic and immunological comp ...... -immune human phage libraries.
@en
P2093
Cindy Wong
James D Marks
Peter Amersdorfer
Robert Sheridan
Sharad Deshpande
Steven Chen
Theresa Smith
P304
P356
10.1016/S0264-410X(01)00482-0
P407
P577
2002-02-01T00:00:00Z